SAR442970, NANOBODY® Placebo
ACT18134
Phase 2 small_molecule active
Quick answer
SAR442970, NANOBODY® Placebo for Ulcerative Colitis is a Phase 2 program (small_molecule) at Sanofi Pharma Bristol-Myers Squibb with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pharma Bristol-Myers Squibb
- Indication
- Ulcerative Colitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active